中基長壽科學(00767.HK)與呈請人達成和解
格隆匯7月11日丨中基長壽科學(00767.HK)公吿,公司於2025年7月11日上午透過其律師行接獲高等法院訴訟2025年第HCCW 406號項下的清盤呈請副本。該呈請的呈請人尚未向公司送達該呈請。該呈請涉及公司受法院命令,須根據於2023年的高等法院訴訟2023年第HCMP 3號項下公司與泰榮國際(香港)有限公司之間法律訴訟的訟費評定,支付訟費共512,193港元(原申索金額為1,022,626.40港元)及按判決利率計算的利息。
公司已與該呈請的呈請人達成和解(額外費用43,000港元將由公司承擔),而和解所需的全部資金已由公司律師保管,以待簽署及提交撤回呈請的同意傳票。根據上述呈請人已同意撤回呈請的同意傳票。
同樣,就本次泰榮法律程序所涉事宜,公司已獲法院判令可向呈請人的一名關連人士追討訟費230,000.00港元,並將繼續追討有關款項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.